On statistical evaluation for interchangeability of biosimilar products
Author byline as per print journal: Yuqi Li, BS Pharm; Professor Shein-Chung Chow, PhD
A biosimilar product is a biological product which is highly similar to an existing reference product in structure and function and has no clinical meaningful difference in terms of safety, purity or potency. By the Biologics Price Competition and Innovation Act of 2009 (BPCI Act), the Food and Drug Administration (FDA)-approved interchangeable biosimilar products can be expected to produce the same clinical result as the reference product in any given patient. In practice, although it is impossible to demonstrate that a proposed interchangeable biosimilar can meet this criterion due to differences in patient physiological conditions and subtle differences between products, it is possible to demonstrate that the interchangeable biosimilar can produce the same clinical result as the reference product in any given patient with certain assurance. In this article, we derived a statistical method, which we refer to as an interchangeability index, for evaluation of the interchangeability of a biosimilar product with a certain statistical assurance. The proposed method was evaluated via extensive simulation studies. The results indicate that the proposed interchangeability index could be a good indication for biosimilar interchangeability when the mean clinical results with moderate variability due to subject by product produced by test and reference product are within a narrow effect equivalence limit.
Subscribe now to GaBI Journal to view full information of this article to be published in the next journal issue.
This manuscript has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process, which may lead to differences between this version and the Version of Record.
Source URL: http://gabi-journal.net/on-statistical-evaluation-for-interchangeability-of-biosimilar-products.html
Copyright ©2022 GaBI Journal unless otherwise noted.
Generics and Biosimilars Initiative (GaBI)
Tel: +32 474989572 | Fax: +32 14 583 048